Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 8/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.53 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6001192 | 0.92 | MAPT (0.60) | ABCG2KDM4EMAPK1MAPTLMNA | |
| SCHEMBL6001165 | 0.81 | KDM4E (0.54) | ABCG2KDM4EMAPK1MAPTLMNA | |
| SCHEMBL6001397 | 0.81 | TDO2 (0.46) | ABCG2KDM4EMAPTLMNAALDH1A1 | |
| SCHEMBL6001931 | 0.78 | ABCG2 (0.93) | ABCG2MAPTLMNATP53SMN1; SMN2 | |
| SCHEMBL6001935 | 0.76 | LMNA (0.55) | ABCG2KDM4EMAPK1MAPTLMNA | |
| SCHEMBL6001437 | 0.76 | KDM4E (0.71) | ABCG2KDM4EMAPK1MAPTLMNA | |
| SCHEMBL15347452 | 0.76 | MAPK1 (0.84) | ABCG2KDM4EMAPK1MAPTLMNA | |
| SCHEMBL25082162 | 0.74 | ABCG2 (0.58) | ABCG2MAPTLMNATP53SMN1; SMN2 | |
| SCHEMBL16404335 | 0.73 | ABCG2 (0.74) | ABCG2KDM4EMAPK1MAPTLMNA | |
| SCHEMBL23743253 | 0.73 | MAPT (0.72) | ABCG2KDM4EMAPK1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060128702-A1 | Heterocyclic and bicyclic compounds, compositions and methods | REDDY US THERAPEUTICS, INC. | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128702-A1 | Heterocyclic and bicyclic compounds, compositions and methods | HPSE, ENGASE, UGCG | ABCG2 2694/4885KDM4E 2893/4885MAPK1 2185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.